Visp | Jotup

United States Oral Solid Dosage Contract Manufacturing Research Report 2023: Market to Reach $16.42 Billion by 2030 - One-Stop-Shop Solutions Transforming the Industry - ResearchAndMarkets.com

Retrieved on:

화요일, 11월 28, 2023

Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Product Type (Tablets, Capsules), By Mechanism (Controlled-, Immediate-release), By End-user, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points:

Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Product Type (Tablets, Capsules), By Mechanism (Controlled-, Immediate-release), By End-user, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
The demand for patient-centric dosage forms has been increasing with time, making it a pivotal trend in the medical field, as it enhances medication adherence.
To render solid oral drugs more user-friendly, drug sponsors are innovatively transforming drugs into micro or mini tablets and sprinkle capsules.
Furthermore, increasing undertaking of strategic initiatives by key players is also expected to drive U.S. oral solid dosage (OSD) contract manufacturing market growth.

Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)

Retrieved on:

월요일, 10월 16, 2023

IPD, Visp, Public, Genetically modified bacteria, PCV, SAN, Pharmaceutical industry, Fine chemical, Adult

SAN CARLOS, Calif. and BASEL, Switzerland, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, and Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced the companies have entered into a new commercial manufacturing agreement. Expanding on their existing collaboration, this agreement supports the potential global commercialization of Vaxcyte’s PCV candidates, VAX-24 and VAX-31, in both the adult and pediatric populations. This agreement complements Vaxcyte’s plans to utilize existing Lonza infrastructure to advance clinical development and the anticipated initial U.S. launch of VAX-24 for the adult population.

Key Points:

Expanding on their existing collaboration, this agreement supports the potential global commercialization of Vaxcyte’s PCV candidates, VAX-24 and VAX-31, in both the adult and pediatric populations.
This agreement complements Vaxcyte’s plans to utilize existing Lonza infrastructure to advance clinical development and the anticipated initial U.S. launch of VAX-24 for the adult population.
The design of the dedicated manufacturing suite is nearly complete, with equipment installation expected to begin in 2024.
“Our expanded relationship with Vaxcyte highlights the value of our services on the path towards commercialization,” said Jean-Christophe Hyvert, President, Biologics Division at Lonza.

Alcatraz AI selected to Join Endeavor - Joining the Prestigious Network of Top Entrepreneurs

Retrieved on:

화요일, 5월 3, 2022

Volunteering, Tailgating, Fortune 500, Time, Alcatraz Island, Entrepreneurship, Visp, Founder, Touchless knockout, Machine learning, LinkedIn, Growth, Intelligence, Medical device, Management, Cryptocurrency, Endeavour

REDWOOD CITY, Calif., May 3, 2022 /PRNewswire-PRWeb/ -- Alcatraz AI, a leader in physical security AI technologies was one of six companies selected to join the Endeavor network at the 25th Virtual International Selection Panel (vISP). Endeavor is the leading global community of high-impact entrepreneurs, working to create a multiplier effect by inspiring high-growth entrepreneurs to dream bigger, supporting and investing in them to scale faster, and providing a platform to pay it forward.

Key Points:

REDWOOD CITY, Calif., May 3, 2022 /PRNewswire-PRWeb/ -- Alcatraz AI, a leader in physical security AI technologies was one of six companies selected to join the Endeavor network at the 25th Virtual International Selection Panel (vISP).
Then, in "deliberation rooms," panelists evaluated the entrepreneurs on their potential for high-impact growth, discussed, and voted unanimously to select the newest Endeavor Entrepreneurs.
"We are extremely excited to have Alcatraz AI, the innovation leader of the physical security world, join the global Endeavor family!
"At Alcatraz AI, we could not be more proud to join Endeavor and their impressive network of innovators," said Vince Gaydarzhiev, President and Founder of Alcatraz AI.

Founder of 360 VUZ, Leading Immersive Video App, Selected as an Endeavor Entrepreneur

Retrieved on:

일요일, 1월 30, 2022

Visp, Volunteering, VUZ, Fortune 500, Instagram, Mentorship, Thought, Industry, Endeavor (non-profit), Video game, Management, Metaverse, Endeavour

DUBAI, UAE, Jan. 30, 2022 /PRNewswire/ -- 360 VUZ, the leading immersive video mobile app building on the Metaverse, announced today the selection of its Founder Khaled Zaatarah as an Endeavor Entrepreneur as a result of the 23rd Virtual International Selection Panel (vISP).

Key Points:

DUBAI, UAE, Jan. 30, 2022 /PRNewswire/ -- 360 VUZ, the leading immersive video mobile app building on the Metaverse, announced today the selection of its Founder Khaled Zaatarah as an Endeavor Entrepreneur as a result of the 23rd Virtual International Selection Panel (vISP).
The selection of Zaatarah into the global network will play a major role in scaling 360 VUZ's business and network.
Khaled Zaatarah, 360 VUZ Founder and Chief Executive Officer, said: "Being selected as an Endeavor Entrepreneur is a badge of honor for me personally and for 360 VUZ.
Stay updated with us on Instagram: https://bit.ly/360VUZ-Instagram
Our 360 VUZ Mobile App Link: https://bit.ly/360VUZ-App-PR
360 VUZ was founded in 2017 by Jordanian entrepreneur Khaled Zaatarah.

Founder of 360 VUZ, Leading Immersive Video App, Selected as an Endeavor Entrepreneur

Retrieved on:

일요일, 1월 30, 2022

Visp, Volunteering, VUZ, Fortune 500, Instagram, Mentorship, Thought, Industry, Multimedia, Endeavor (non-profit), Video game, Management, Metaverse, Endeavour

DUBAI, UAE, Jan. 30, 2022 /PRNewswire/ -- 360 VUZ, the leading immersive video mobile app building on the Metaverse, announced today the selection of its Founder Khaled Zaatarah as an Endeavor Entrepreneur as a result of the 23rd Virtual International Selection Panel (vISP).

Key Points:

DUBAI, UAE, Jan. 30, 2022 /PRNewswire/ -- 360 VUZ, the leading immersive video mobile app building on the Metaverse, announced today the selection of its Founder Khaled Zaatarah as an Endeavor Entrepreneur as a result of the 23rd Virtual International Selection Panel (vISP).
The selection of Zaatarah into the global network will play a major role in scaling 360 VUZ's business and network.
Khaled Zaatarah, 360 VUZ Founder and Chief Executive Officer, said: "Being selected as an Endeavor Entrepreneur is a badge of honor for me personally and for 360 VUZ.
Stay updated with us on Instagram: https://bit.ly/360VUZ-Instagram
Our 360 VUZ Mobile App Link: https://bit.ly/360VUZ-App-PR
360 VUZ was founded in 2017 by Jordanian entrepreneur Khaled Zaatarah.

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

Retrieved on:

화요일, 12월 15, 2020

Health, Manufacturing, Clinical trials, Other Manufacturing, Pharmaceutical, Biotechnology, Health care, Health, Immunosuppressants, Peptides, Voclosporin, Pharmaceutical industry in China, Lonza, Aurinia, Visp, Pharmaceutical industry in India

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia) and Lonza Ltd. (SIX: LONN) ("Lonza") today announced they have expanded their exclusive manufacturing relationship.

Key Points:

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia) and Lonza Ltd. (SIX: LONN) ("Lonza") today announced they have expanded their exclusive manufacturing relationship.
The parties entered into a collaborative agreement to build a dedicated manufacturing capacity within Lonzas existing small molecule API facility in Visp, Switzerland.
The agreement, which is conditional upon U.S. regulatory approval of voclosporin, does not impact the launch supply for voclosporin as this is secured by existing inventory.
A dedicated production capability will help keep our manufacturing costs down and ensure long-term flexibility to meet future demand for years to come.